Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 70

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 3
Chunk 70
---
 surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents, all of which could
have a material adverse effect on our business and financial condition.

If our trademarks and trade names are not adequately protected,
then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Our registered or unregistered trademarks or trade
names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able
to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers
in our markets of interest. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names,
then we may not be able to compete effectively and our business may be adversely affected. If other entities use trademarks similar to
ours in different jurisdictions, or have senior rights to ours, it could interfere with our use of our current trademarks throughout the
world.

If we are unable to maintain effective proprietary rights for our
product candidates or any future product candidates, we may not be able to compete effectively in our markets.

In addition to the protection afforded by any patents
that have been or may be granted, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that
is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product
candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents.
However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering
into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity
and confidentiality of our data, trade secrets and intellectual property by maintaining the physical security of our premises and physical
and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems,
agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets
and intellectual property may otherwise become known or be independently discovered by competitors.

Although we expect all of our employees and consultants
to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary
know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that